J1449 HCPCS code: Injection, eflapegrastim-xnst, 0.1 mg
J1449 is the HCPCS Level II code for injection, eflapegrastim-xnst, 0.1 mg. In 2024 Medicare paid an average of $20.71 per service for J1449 across 2,817,151 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 132 per day on outpatient hospital claims. Medicare volume rose 73% from 2023 to 2024 (1,630,540 to 2,817,151 services). In 2024, about 1,431 clinicians billed Medicare for J1449 for 6,266 beneficiaries; Pennsylvania, New Jersey, Illinois accounted for 23% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-04-01 |
| Last action effective | 2023-04-01 |
Who bills J1449 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,431 |
| Medicare beneficiaries | 6,266 |
| States with claims | 37 |
| Share of services in top 3 states (Pennsylvania, New Jersey, Illinois) | 23% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1449, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 1,630,540 | 4,237 | $32.05 | $25.54 |
| 2024 | 2,817,151 | 6,266 | $26.03 | $20.71 |
States with the most J1449 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Pennsylvania | 245,608 | $20.93 |
| New Jersey | 211,879 | $20.64 |
| Illinois | 196,165 | $20.66 |
| Tennessee | 194,701 | $20.96 |
| Mississippi | 166,584 | $20.78 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 132 | Prescribing Information |
| practitioner claims | 132 | Prescribing Information |
Medicare policy articles for this code
- A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B))
Covered diagnoses (1,265 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| B20 | Human immunodeficiency virus [HIV] disease | 1 |
| C00.0 | Malignant neoplasm of external upper lip | 1 |
| C00.1 | Malignant neoplasm of external lower lip | 1 |
| C00.2 | Malignant neoplasm of external lip, unspecified | 1 |
| C00.3 | Malignant neoplasm of upper lip, inner aspect | 1 |
| C00.4 | Malignant neoplasm of lower lip, inner aspect | 1 |
| C00.5 | Malignant neoplasm of lip, unspecified, inner aspect | 1 |
| C00.6 | Malignant neoplasm of commissure of lip, unspecified | 1 |
| C00.8 | Malignant neoplasm of overlapping sites of lip | 1 |
| C00.9 | Malignant neoplasm of lip, unspecified | 1 |
Showing 10 of 1,265. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J1449
- 2023-04-01: J1449 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1449?
J1449 is the HCPCS Level II code for injection, eflapegrastim-xnst, 0.1 mg. Short descriptor: "Inj eflapegrastim-xnst 0.1mg".
How much does Medicare pay for J1449?
In 2024, the average Medicare payment was $20.71 per service (average allowed $26.03).
Does Medicare cover J1449?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J1449?
Medicare policy articles that cite J1449 list 1,265 covered ICD-10-CM diagnosis codes across 1 article. The most cited include B20 (Human immunodeficiency virus [HIV] disease), C00.0 (Malignant neoplasm of external upper lip), C00.1 (Malignant neoplasm of external lower lip). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J1449 can be billed per day?
132 on outpatient hospital claims; 132 on practitioner claims (NCCI medically unlikely edits).
Related J14 codes
- J1410 — Injection, estrogen conjugated, per 25 mg
- J1411 — Injection, etranacogene dezaparvovec-drlb, per therapeutic dose
- J1412 — Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector genomes
- J1413 — Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
- J1414 — Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
- J1426 — Injection, casimersen, 10 mg
- J1427 — Injection, viltolarsen, 10 mg
- J1428 — Injection, eteplirsen, 10 mg
- J1429 — Injection, golodirsen, 10 mg
- J1430 — Injection, ethanolamine oleate, 100 mg
- J1434 — Injection, fosaprepitant (focinvez), 1 mg
- J1435 — Injection, estrone, per 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1449
- Watch J1449 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1449
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.